Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492335 | 0.75 | DHFR (0.54) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL17868157 | 0.74 | BRD4 (0.65) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL19312199 | 0.74 | PAK4 (0.43) | CCNA2CDK2CCNA1SMN1; SMN2NPC1 | |
| SCHEMBL2387629 | 0.74 | CCNA2 (0.39) | CCNA2CDK2CCNA1KMT2AAURKA | |
| SCHEMBL3621028 | 0.73 | CCNA2 (0.58) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL324086 | 0.72 | TMEM97 (0.64) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL15499538 | 0.72 | KMT2A (0.60) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL1488412 | 0.72 | KMT2A (0.60) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL31276469 | 0.72 | TMEM97 (0.60) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL1489028 | 0.71 | KMT2A (0.59) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102498113-B | Macrocyclic inhibitors of JAK | HOFFMANN LA ROCHE | 2014-11-26 | — | — | CN | disclosed |
| EP-2480554-B1 | MACROCYCLIC INHIBITORS OF JAK | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-2480554-B1 | MACROCYCLIC INHIBITORS OF JAK | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2480554-A1 | MACROCYCLIC INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011033053-A1 | MACROCYCLIC INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011033053-A1 | MACROCYCLIC INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAK2, JAK1, JAK3 | CCNA2 479/4885CDK2 56/4885CCNA1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.